よむ、つかう、まなぶ。
参考資料３ WHO Statement on the antigen composition of COVID-19 vaccines (1 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/newpage_00104.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会 研究開発及び生産・流通部会 季節性インフルエンザワクチンの製造株について検討する小委員会（第2回 5／29）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
第 2 回 厚生 科学審議会予防接種・ワクチン人分科 会
研究 開 発 及 び 生 産 流通 部 会| 参考資料
季節性インフルエンザワクチン及び新型コロナワクチンの製造株について検討する小委員会
2024 (令和6) 年5月29 日
Statement on thne antigen
coImpOosition of COVID-19
VaCCIneS
26 ADpril 2024
Statement
Reading time: 7 min (1878 words)
Key DoInts
。 SARS-CoV-2 continues to circulate and evolve with important genetic and
antigenic evolution of the spike protein.
s 「Ihe Objective of an update to COVID-19 vaccine antigen composition is to
enhance vaccine-induced immune resDonses to circulating SARS-CoV-2 variantS.
。 ASthe virus iS exDected to continue to evolve from」N.1, the TAG-CO-VAC advises
the use of a monovalent JN.1 lineage as the antigen in future formulations of
COVID-19 vaccines.
s In accordance with WHO SAGE policy, vaccination Drodgrammes should continue
to use any Of the WHO emergency-use listed or predualified COVID-19 vaccines
and vaccination should not be delayed in anticipation of access to vaccines with
an updated composition.
The WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC)
meets regularly to assess the impact of SARS-CoV-2 evolution on the performance of
DDroved COVID-19 vaccines. This includes meeting in Derson apDrOximately eVery SIx
months to determine the implications of SARS-CoV-2 evolution on COVID-19 vaccine
antiden composition and to advise WHO on whether changes are needed to the
antigen composition of future COVID-19 vaccines. The twice-yearly evidence review by
1
研究 開 発 及 び 生 産 流通 部 会| 参考資料
季節性インフルエンザワクチン及び新型コロナワクチンの製造株について検討する小委員会
2024 (令和6) 年5月29 日
Statement on thne antigen
coImpOosition of COVID-19
VaCCIneS
26 ADpril 2024
Statement
Reading time: 7 min (1878 words)
Key DoInts
。 SARS-CoV-2 continues to circulate and evolve with important genetic and
antigenic evolution of the spike protein.
s 「Ihe Objective of an update to COVID-19 vaccine antigen composition is to
enhance vaccine-induced immune resDonses to circulating SARS-CoV-2 variantS.
。 ASthe virus iS exDected to continue to evolve from」N.1, the TAG-CO-VAC advises
the use of a monovalent JN.1 lineage as the antigen in future formulations of
COVID-19 vaccines.
s In accordance with WHO SAGE policy, vaccination Drodgrammes should continue
to use any Of the WHO emergency-use listed or predualified COVID-19 vaccines
and vaccination should not be delayed in anticipation of access to vaccines with
an updated composition.
The WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC)
meets regularly to assess the impact of SARS-CoV-2 evolution on the performance of
DDroved COVID-19 vaccines. This includes meeting in Derson apDrOximately eVery SIx
months to determine the implications of SARS-CoV-2 evolution on COVID-19 vaccine
antiden composition and to advise WHO on whether changes are needed to the
antigen composition of future COVID-19 vaccines. The twice-yearly evidence review by
1